Form 4: OptimizeRx Chief Commercial Officer Receives Stock Options and Restricted Stock Units
SEC Form 4 Filing
Theresa Greco, Chief Commercial Officer of OptimizeRx Corp, was granted stock options and restricted stock units on December 23, 2024.
Summary
- Theresa Greco, the Chief Commercial Officer of OptimizeRx Corp, received 15,528 restricted stock units and 29,153 stock options on December 23, 2024.
- The restricted stock units represent a contingent right to receive shares of OptimizeRx common stock and will vest in three equal annual installments starting December 23, 2025.
- The stock options have an exercise price of $4.83 and will also vest in three equal annual installments beginning December 23, 2025, and expire on December 23, 2027.
- Following these transactions, Ms. Greco beneficially owns 50,873 shares of common stock.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management interests with shareholders. There are no negative implications.
Positives
- The grant of stock options and restricted stock units aligns the Chief Commercial Officer's interests with those of the shareholders.
- The vesting schedule encourages long-term commitment from the executive.
Future Outlook
The vesting of the stock options and restricted stock units is contingent on continued employment and will occur over the next three years.
Industry Context
Stock-based compensation is a common practice for incentivizing executives in publicly traded companies, particularly in the technology and healthcare sectors.
Comparison to Industry Standards
- The vesting schedule of three years is a standard practice for stock options and restricted stock units.
- The exercise price of $4.83 for the stock options is typical for grants made at the current market price.
Stakeholder Impact
- Shareholders may view the stock option and restricted stock unit grants positively as they incentivize management to improve company performance.
- Employees may see this as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 12/23/2024 | Date of grant for restricted stock units and stock options. |
| 12/23/2025 | First vesting date for both restricted stock units and stock options. |
| 12/23/2027 | Expiration date for the stock options. |
| 12/27/2024 | Date of filing of the Form 4. |
Keywords
stock options, restricted stock units, executive compensation, insider trading, beneficial ownership, OPRX, OptimizeRx
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.